MaaT Pharma Reports FDA Feedback After Pre-IND Meeting on MaaT034
MaaT Pharma said FDA feedback following a pre-IND meeting supports continued development of MaaT034 in solid tumors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.